Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Lifshitz Law PLLC Announces Investigations of BlackRock, TCP Capital Corp. (NASDAQ: TCPC), Oracle Corporation (NYSE: ORCL), REGENXBIO Inc. (NASDAQ: RGNX), and Inovio Pharmaceuticals, Inc. (NASDAQ: INO)

accessnewswire.com
TCPC Investigation announced due to allegations of false and misleading statements regarding investment valuation, portfolio restructuring, understated unrealized losses, and overstated Net Asset Value. ORCL Investigation announced over allegations of misleading statements regarding AI infrastructure strategy, massive CapEx increases without revenue growth, and risks to debt, credit rating, and cash flow. RGNX Investigation into allegations of materially misleading statements about the development and commercialization of RGX-111, overstating its efficacy, safety, and trial success. INO Investigation announced due to allegations of false and misleading statements regarding manufacturing deficiencies for the CELLECTRA device, impacting regulatory submission timelines and commercial prospects.

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2026 / Lifshitz Law Firm

BlackRock, TCP Capital Corp. (NASDAQ:TCPC)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) the Company's investments were not being timely and/or appropriately valued; (ii) the Company's efforts at portfolio restructuring were not effectively resolving challenged credits or improving the quality of the portfolio; (iii) the Company's unrealized losses were understated; and (iv) the Company's Net Asset Value was overstated.

If you are a TCPC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Oracle Corporation (NYSE:ORCL)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's AI infrastructure strategy would result in massive increases in CapEx without equivalent, near-term growth in revenue; and (ii) the Company's substantially increased spending created serious risks involving Oracle's debt and credit rating, free cash flow, and ability to fund its projects, among other concerns.

If you are an ORCL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

REGENXBIO Inc. (NASDAQ:RGNX)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) REGENXBIO's representations concerning its plan to develop and commercialize RGX‑111, a one‑time gene therapy for the treatment of severe Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome, were materially misleading; (ii) the Company's positive statements regarding the anticipated success of RGX‑111's Phase I/II clinical trial, purportedly supported by continuing favorable biomarker and safety data, lacked a reasonable basis; and (iii) the efficacy and safety profile of RGX‑111 was materially overstated.

If you are an RGNX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; and (iv) as a result of the foregoing, INO-3107's overall regulatory and commercial prospects were overstated.

If you are an INO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

ATTORNEY ADVERTISING.© 2026 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516) 493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.

Lifshitz Law PLLC

Phone: 516-493-9780

Facsimile: 516-280-7376

Email: [email protected]

SOURCE: Lifshitz Law Firm